Literature DB >> 18238890

Potential for underdosing and emergence of resistance in Acinetobacter baumannii during treatment with colistin.

Miruna D David, Martin J Gill.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18238890     DOI： 10.1093/jac/dkn009

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN： 0305-7453            Impact factor:   5.790


× No keyword cloud information.
  9 in total

1.  fAUC/MIC is the most predictive pharmacokinetic/pharmacodynamic index of colistin against Acinetobacter baumannii in murine thigh and lung infection models.

Authors:  Rajesh V Dudhani; John D Turnidge; Roger L Nation; Jian Li
Journal:  J Antimicrob Chemother       Date:  2010-06-23       Impact factor: 5.790

2.  In Vitro Activity of Imipenem-Relebactam Alone or in Combination with Amikacin or Colistin against Pseudomonas aeruginosa.

Authors:  Tomefa E Asempa; David P Nicolau; Joseph L Kuti
Journal:  Antimicrob Agents Chemother       Date:  2019-08-23       Impact factor: 5.191

3.  High performance liquid chromatography-mass spectrometry assay for polymyxin B1 and B2 in human plasma.

Authors:  Tiffany A Thomas; Emily C Broun; Kirsten M Abildskov; Christine J Kubin; Jennifer Horan; Michael T Yin; Serge Cremers
Journal:  Ther Drug Monit       Date:  2012-08       Impact factor: 3.681

4.  Activity of the colistin-rifampicin combination against colistin-resistant, carbapenemase-producing Gram-negative bacteria.

Authors:  Marcela Nastro; Carlos Hernan Rodríguez; Renata Monge; Jonathan Zintgraff; Liliana Neira; Mirta Rebollo; Carlos Vay; Angela Famiglietti
Journal:  J Chemother       Date:  2013-12-06       Impact factor: 1.714

5.  Antimicrobial Susceptibility of Acinetobacter calcoaceticus-Acinetobacter baumannii Complex and Stenotrophomonas maltophilia Clinical Isolates: Results From the SENTRY Antimicrobial Surveillance Program (1997-2016).

Authors:  Ana C Gales; Harald Seifert; Deniz Gur; Mariana Castanheira; Ronald N Jones; Helio S Sader
Journal:  Open Forum Infect Dis       Date:  2019-03-15       Impact factor: 3.835

6.  A Randomized Controlled Trial of Colistin Combined with Sulbactam: 9 g per Day versus 12 g per Day in the Treatment of Extensively Drug-Resistant Acinetobacter baumannii Pneumonia: An Interim Analysis.

Authors:  Chutchawan Ungthammakhun; Vasin Vasikasin; Dhitiwat Changpradub
Journal:  Antibiotics (Basel)       Date:  2022-08-17

7.  Optimal therapy for multidrug-resistant Acinetobacter baumannii.

Authors:  Burke A Cunha
Journal:  Emerg Infect Dis       Date:  2010-01       Impact factor: 6.883

8.  Extensively drug-resistant Acinetobacter baumannii.

Authors:  Yohei Doi; Shahid Husain; Brian A Potoski; Kenneth R McCurry; David L Paterson
Journal:  Emerg Infect Dis       Date:  2009-06       Impact factor: 6.883

Review 9.  The Efficacy of Using Combination Therapy against Multi-Drug and Extensively Drug-Resistant Pseudomonas aeruginosa in Clinical Settings.

Authors:  Frank Jones; Yanmin Hu; Anthony Coates
Journal:  Antibiotics (Basel)       Date:  2022-02-28
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.